Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in cases with persistent bacteremia, septic emboli, vegetations larger than 2 cm, or severe tricuspid regurgitation, although it is associated with risks such as bleeding, reoperation, and operative mortality.

Percutaneous mechanical aspiration (PMA) allows reduction of vegetation burden in patients with high surgical risk or contraindications to surgery. In order to compare both strategies, the authors conducted a systematic review and meta-analysis of the clinical outcomes of PMA versus surgery in TVIE.

The primary endpoint was all-cause mortality (in-hospital, at 30 days, and at 1 year), while secondary endpoints included length of hospital stay and the rate of readmission due to endocarditis. 

A systematic search was performed through July 2025, identifying 10 retrospective comparative studies conducted in the United States evaluating PMA versus surgical treatment in tricuspid endocarditis.

Read also: CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve.

Percutaneous Mechanical Aspiration vs Surgery in Tricuspid Valve Endocarditis: Impact on Mortality and Clinical Outcomes

A total of 6,035 patients were analyzed, of whom 974 were treated with PMA and 5,061 with surgery. The patients had a mean age of approximately 33–35 years and a high prevalence of intravenous drug use, present in more than 70% of cases. Significant tricuspid regurgitation, septic emboli, and septic shock were frequent findings. 

Percutaneous aspiration (often performed using aspiration systems such as AngioVac) was mainly used in patients considered to be at high surgical risk or with contraindications to surgery, whereas surgical intervention allowed valve repair or replacement and definitive treatment of the infectious focus.

In the analysis of in-hospital mortality, no significant differences were observed between the two strategies (RR 1.07; 95% CI 0.32–3.57; p=0.91). In contrast, 30-day mortality was significantly higher in the group treated with percutaneous aspiration (RR 2.71; 95% CI 1.53–4.82; p<0.001).

Read also: CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI.

Despite this finding, 1-year mortality showed no significant differences between the two strategies (RR 1.13; 95% CI 0.72–1.77; p=0.60). A significantly shorter hospital stay was observed with percutaneous aspiration, with a mean difference of −7.0 days (95% CI −12.96 to −1.05; p=0.03), and the risk of readmission due to endocarditis was similar between both groups (RR 0.82; 95% CI 0.36–1.85; p=0.63).

Conclusion

In summary, in this meta-analysis including patients with tricuspid endocarditis, percutaneous mechanical aspiration was associated with a shorter length of hospital stay, whereas surgical treatment showed better short-term survival, particularly at 30 days. No differences were observed in 1-year mortality or in the rates of readmission for endocarditis between the two strategies.

Since the available evidence derives exclusively from observational studies with moderate to high risk of bias, the authors conclude that randomized clinical trials are needed to more precisely define the relative role of these therapeutic strategies.

Original Title: Percutaneous Mechanical Aspiration Versus Surgical Management of Tricuspid Valve Endocarditis: A Systematic Review and Updated Meta-Analysis.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHAMPION-AF: Left atrial appendage closure versus anticoagulation in atrial fibrillation

Can left atrial appendage closure challenge anticoagulation as the standard of care in atrial fibrillation? Atrial fibrillation (AF) is the most common sustained arrhythmia and...

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...